10-K - Nektar Therapeutics | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Nektar Therapeutics reported a net loss of $164.1 million for FY 2025, driven by an operating loss of $140.1 million on total revenue of $55.2 million. The company's revenue was primarily from license, collaboration, and other sources, with no product sales. Operating expenses totaled $195.3 million, dominated by research and development ($117.3 million) and general and administrative costs ($68.7 million). Cash used in operations was $208.5 million, partially offset by $180.6 million in net financing cash inflows from equity offerings. The company ended the year with $245.8 million in cash and marketable securities and estimates sufficient working capital for at least the next twelve months. Forward-looking statements indicate significant planned increases in R&D spending for the Phase 3 rezpegaldesleukin program in atopic dermatitis in 2026.

Key Takeaways

1Reported a net loss of $164.1 million for FY 2025 with total revenue of $55.2 million.

2Research and development expense was $117.3 million, including $51.5 million for rezpegaldesleukin Phase 2b trials.

3Cash used in operating activities was $208.5 million, while financing activities provided $180.6 million.

4Ended the year with $245.8 million in cash and marketable securities and total assets of $280.4 million.

5Expects R&D expenses to increase significantly in 2026 to support the Phase 3 rezpegaldesleukin program.

Key Financial Metrics

EPS

-$10.00

N/A prior year

Revenue

$55.2M

N/A

Net Income

-$164.1M

N/A